Personalized combination therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a personalized combination treatment for unresectable (cannot be removed with surgery) liver cancer. It uses a special test to guide which drugs you receive, aiming to improve how well the treatment works for your specific tumor type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer)
- Your liver cancer cannot be removed with surgery, has come back after surgery or local treatment, or is not suitable for curative therapies
- Your liver cancer is at stage B or C (moderate to advanced)
- You have not had any prior whole-body (systemic) treatment for your liver cancer
- You have at least one tumor that can be measured on imaging scans
- You have a tumor tissue sample available for testing, or your doctor can use an MRI to check a special marker
- Your liver function is adequate (Child-Pugh class A or B with a score of 7 or less)
- You are generally active (ECOG score 0-1)
- Your blood counts and organ function (such as kidney and liver) are within acceptable ranges
- If you have hepatitis B, it is controlled with medication; if you have hepatitis C, it is managed according to guidelines
- You are expected to live at least 3 months
- You agree to use effective birth control during and for 6 months after treatment (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This Phase 3 trial tests whether combining camrelizumab and apatinib with TACE before/around liver cancer surgery can improve outcomes for people with certain stages of hepatocellular carcinoma (HCC). It may help by strengthening the immune attack on cancer and by blocking blood supply to tumors.
This trial tests a combination of treatments for advanced liver cancer: a targeted therapy (apatinib), an immunotherapy (camrelizumab), and two local treatments (TAE and HAIC). It may be an option if you have a high tumor burden or a tumor thrombus in the portal vein and haven't had systemic treatment before.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
Hear when a new Unresectable Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.